Sildenafil

Drugs of the Future

Volumn 22, Issue 2, 1997, Pages 138-143

  Martel, A M ^a   Graul, A ^a   Rabasseda, X ^a   Castaner R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG;

CORPUS CAVERNOSUM; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DYSPEPSIA; ENZYME ACTIVITY; ENZYME INHIBITION; HEADACHE; HUMAN; IMPOTENCE; IN VITRO STUDY; MALE; MYALGIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PENIS ERECTION; RABBIT; SHORT SURVEY;

EID: 0030999960     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.02.386136     Document Type: Short Survey

References (17)

1. Bell, A.S., Brown, D., Terrett, N.K. (Pfizer, Ltd.; Pfizer, Inc.). Pyrazolopyrimidinone antianginal agents. EP 463756, JP 94041133, US 5250534, US 5346901.
2. Terrett, N.K., Bell, A.S., Brown, D., Ellis, P. Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996, 6: 1819-24.
3. American Urological Association panel releases treatment guidelines for impotence. American Urological Association Press Release 1996, November 4.
4. Kim, N., Azadzoi, K.M., Goldstein, I., Saenz de Tejada, I. A nitric oxide-like factor mediates non-adrenergic - non-cholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991, 88: 112-8.
5. Bush, P.A., Aronson, W.J., Raifer, J., Ignarro, L.J. The L-arginine-nitric oxide-cyclic GMP pathway mediates inhibitory non-adrenergic non-cholinergic neurotransmission in the corpus cavernosum of human and rabbit. Circulation 1993, 87(5, Suppl.): V30-2.
6. Ellis, P., Terrett, N.K. (Pfizer, Ltd.; Pfizer Res. Dev. Co. NV/SA; Pfizer, Inc.). Pyrazolopyrimidinones for the treatment of impotence. EP 702555, WO 9428902.
7. Terrett, N.K., Bell, A.S., Brown, D., Ellis, P. UK-92,480, a potent and selective inhibitor of type V(A) cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. 210th ACS Natl Meet Amer Chem Soc (Aug 20-24, Chicago) 1995, Abst MEDI 229.
8. Jeremy, J.Y., Ballard, S.A., Naylor, A.M., Miller, M.A.W., Angelini, G.D. The effects of sildenafil, an inhibitor of type 5 cGMP phosphodiesterase, on cGMP and cAMP levels in rabbit corpus cavernosum, in vitro. Brit J Pharmacol 1996, 119(Suppl.): Abst 84P.
9. Ballard, S.A., Turner, L.A., Naylor, A.M. Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase, enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum. Brit J Pharmacol 1996, 118(Suppl.): Abst 153P.
10. Tang, K., Turner, L.A., Ballard, S.A., Naylor, A.M. Effects of the novel phosphodiesterase type 5 inhibitor, sildenafil, on methacholine-induced relaxation of rabbit isolated corpus cavernosum. Brit J Pharmacol 1996, 118(Suppl.): Abst 154P.
11. Boolell, M., Gepi-Attee, S., Gingell, J.C., Allen, M.J. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Brit J Urol 1996, 78: 257-61.
12. Boolell, M., Pearson, J., Gingell, J.C., Gepi-Attee, S., Wareham, K., Price, D. Sildenafil (Viagra™) is an efficacious oral therapy in diabetic patients with erectile dysfunction (ED). Int J Impot Res 1996, 8(3): Abst P14.
13. Eardley, I., Morgan, R.J., Dinsmore, W.W., Pearson, J., Wulff, M.B., Boolell, M. UK-92,480, a new oral therapy for erectile dysfunction, a double-blind, placebo controlled trial with treatment taken as required. J Urol 1996, 155(5, Suppl.): Abst 737.
14. Gingell, C.J.C., Jardin, A., Olsson, A.M. et al. UK-92,480, a new oral treatment tor erectile dysfunction: A double-blind, placebo-controlled, once daily dose response study. J Urol 1996, 155(5, Suppl.): Abst 738.
15. Boolell, M., Yates, P.K., Wulff, M.B., Brook, J., Eardley, I. Sildenafil (Viagra™), a novel oral treatment with rapid onset of action for penile erectile dysfunction (ED). Int J Impot Res 1996, 8(3): Abst D101.
16. Christiansen, E., Hodges, M., Hollingshead, M., Kirkpatrick, J., Dickinson, S., Osterloh, I. Sildenafil (Viagra™) a new oral treatment for erectile dysfunction (ED): Results of a 16 week open dose escalation study. Int J Impot Res 1996, 8(3): Abst D99.
17. Virag, R., Hodges, M., Hollingshead, M., Kirkpatrick, J., Osterloh, I. Sildenafil (Viagra™) a new oral treatment for erectile dysfunction (ED): An 8 week double-blind, placebo-controlled parallel group study. Int J Impot Res 1996, 8(3): Abst A70.